Pascal Soriot isn’t letting the all-consuming R&D and manufacturing work on a Covid-19 vaccine slow down his hunt for AstraZeneca’s next blockbuster cancer drugs.
The latest deal with Daiichi Sankyo consists of $1 billion in upfront cash payment spread over 2 years: $350 million upon completion, and $325 million each at the 12-month and 24-month mark. Regulatory milestones add up to another $1 billion while sales-related fees tot up to $4 billion.
{iframe}https://endpts.com/astrazeneca-mines-another-6b-adc-from-daiichi-sankyo-with-blockbuster-ambitions-to-redefine-treatment-standards/{/iframe}